Role of the investigator in phase 1 trials of anticancer drugs
Mené sur 29 patients atteints d'une tumeur solide de stade avancé surexprimant EGFR, cet essai de phase I évalue la toxicité d'un traitement à base d'immunoliposomes anti-EGFR chargés en doxorubicine
For two decades, liposome formulations of many cytotoxic drugs (eg, cisplatin, vinca alkaloids, taxanes, and camptothecin) have been investigated to improve the activity-to-safety ratio. Many clinical studies have explored the theoretical advantages of pegylated liposomal doxorubicin over classical doxorubicin, and results suggest that the pegylated liposomal form has a longer half-life, a better safety profile (less cardiotoxic), and might have better tissue distribution and cell penetration than the free form of the drug. Nevertheless, debate surrounds this improved therapeutic index...
The Lancet Oncology , commentaire, 2011